Pharmaceuticals

Psoriasis Market Developments Shaping Growth Across The Forecast Period

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Does The Market Size Of The Psoriasis Market Compare Between 2026 And 2030?

The psoriasis market size has demonstrated significant growth in recent years. It is projected to expand from $28.93 billion in 2025 to $31.41 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. This historical growth is attributable to an increasing prevalence of autoimmune skin disorders, widespread corticosteroid usage, improved dermatology diagnosis rates, the expansion of hospital dermatology units, and growing awareness of chronic skin diseases.

The psoriasis market size is anticipated to experience substantial growth in the upcoming years. It is forecast to expand to $44.79 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.3%. This projected growth is driven by factors such as an increase in biologic drug approvals, enhanced patient awareness, a rise in severe psoriasis diagnoses, the proliferation of specialty clinics, and elevated healthcare spending on dermatology. Significant trends during this period include the increased adoption of biologic therapies for psoriasis, a rise in long-term disease management strategies, growing demand for injectable psoriasis treatments, the expansion of hospital and specialty dermatology care, and a heightened focus on moderate-to-severe psoriasis.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2414&type=smp

What Major Factors Are Driving The Psoriasis Market Forward?

The increasing number of individuals afflicted with psoriasis is projected to fuel the expansion of the psoriasis market in the coming years. Psoriasis, an ongoing autoimmune skin condition, manifests through rapid accumulation of skin cells, resulting in inflammation, flaking, and discomfort, frequently necessitating ongoing medical intervention and observation. The escalation in psoriasis cases stems from an overly active immune system that erroneously attacks healthy skin cells, often initiated or worsened by external elements such as infections, psychological strain, or skin injuries. The expanding incidence of psoriasis benefits the psoriasis market by boosting the need for treatments like biologics, topical agents, immunomodulators, and phototherapy options aimed at reducing symptom flares, alleviating discomfort, and improving patients’ overall well-being. For example, in 2025, the Global Psoriasis Atlas, a UK-based research organization focused on psoriasis, estimated that 43 million individuals had psoriasis based on diagnoses from doctors and dermatologists, whereas around 102 million people reported having psoriasis through self-reported accounts. Consequently, the rising prevalence of psoriasis patients is propelling the growth of the psoriasis market.

Which Segment Types Are Examined In The Psoriasis Market Segment Study?

The psoriasis market covered in this report is segmented –

1) By Drug class: Interleukin Inhibitors, Corticosteroids, Anti-Inflammatory, Tumor Necrosis Factor Inhibitor

2) By Drug Types: Small molecules, Biologics

3) By Disease Indication: Plaque Psoriasis, Nail Psoriasis, Guttate Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis

4) By Route Of Administration: Oral, Topical, Injectable

5) By Distribution Channel: Hospitals, Retail Pharmacies, E-Commerce

Subsegments:

1) By Interleukin Inhibitors: IL-12/23 Inhibitors (Ustekinumab), IL-17 Inhibitors (Secukinumab, Ixekizumab)

2) By Corticosteroids: Topical Corticosteroids (Hydrocortisone, Betamethasone), Systemic Corticosteroids (Prednisone)

3) By Anti-Inflammatory: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

4) By Tumor Necrosis Factor (TNF) Inhibitors: Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade)

What Trends Are Shaping The Future Of The Psoriasis Market?

Companies operating within the psoriasis market are prioritizing advancements in product development and delivery methods, such as autoinjector systems for biosimilars. This focus aims to enhance patient compliance, ease of use, and therapeutic results, all while upholding the effectiveness and safety standards of the original biologics. These innovative solutions facilitate at-home self-administration, minimize injection discomfort, and are instrumental in promoting the wider acceptance of biosimilar therapies across Europe and various other regions. For example, in May 2025, Sandoz, a biopharmaceutical firm based in Switzerland, introduced the Pyzchiva autoinjector, marking the pioneering entry of a commercially available autoinjector for ustekinumab biosimilars in Europe. The Pyzchiva autoinjector is engineered for straightforward, precise, and user-friendly delivery of biosimilar ustekinumab, thereby fostering better compliance for individuals managing chronic psoriasis. This introduction underscores a market movement towards improving patient-focused administration methods for biologics and biosimilars, boosting availability and ease of use for those living with psoriasis.

Which Players Are Part Of The Competitive Landscape Of The Psoriasis Market?

Major companies operating in the psoriasis market are AbbVie Inc., Pfizer Inc., Novartis AG, Eli Lilly and Company, Johnson & Johnson, Amgen Inc., Merck & Co. Inc., Janssen Biotech Inc., Takeda Pharmaceutical Company Limited, Union Chimique Belge SA, Sun Pharmaceutical Industries Ltd., Almirall SA, Bausch Health Companies Inc., Biogen Inc., Biocon Biopharmaceuticals Pvt. Ltd., Celltrion Inc., Dr.Reddy’s Laboratories Inc., Arcutis Biotherapeutics Inc., Bayer AG, Bristol Myers Squibb Co., Galderma SA, GlaxoSmithKline Plc, Incyte Pharmaceuticals Corp., LEO Pharmacy

Get The Full Psoriasis Market Report:

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Which Region Is The Largest In The Psoriasis Market?

North America was the largest region in the psoriasis market in 2025. Middle East is expected to be the fastest-growing region in the psoriasis market during the forecast period. The regions covered in the psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Psoriasis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Browse Through More Reports Similar to the Global Psoriasis Market 2026, By The Business Research Company

Psoriasis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Dermatology Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795